Supplemental B12 favorably modulates persistently dysregulated inflammatory genes in the leukocytes of patients with VCD After 6 to 12 months from the initial diagnosis, CCL11 ( P = 0.0127) and LIF ( P = 0.0485) continued to show upregulation in leukocytes from individuals with persistent VCD compared to those from non-impaired subjects (Fig
The most-cited research uses are musculoskeletal soft-tissue healing (tendon, ligament, skeletal muscle) and gastrointestinal healing, and we review the former in depth in our reference on the evidence for BPC-157 in musculoskeletal healing
Mechanistically, its claimed effects track the biology of that TB4 motif: regulating actin dynamics, driving cell migration, and supporting new vessel growth and tissue repair
Conclusion BPC-157 is emerging as one of the most promising gut-healing peptides, with potential benefits spanning ulcers, IBS, gastritis, GERD, and IBD
What patients want to know is what it costs, how it is administered, and what a realistic timeline looks like